GlassScriptPhysician profile
Sarah Qureshi
NPI 1467809392
$2,938.47
in general payments reported to CMS, 2019-2025
19 companies · $1,151 in 2025
The $1,151 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $809 · 2020: $117 · 2021: $14.94 · 2022: $75.18 · 2023: $252 · 2024: $519 · 2025: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635 · Education: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.76 |
| Education | $287.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,001.14 | 2019-2025 | |
| Janssen Biotech, INC. | $563.00 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $265.67 | 2020-2025 | Sotyktu |
| Lilly USA, LLC | $161.27 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $157.67 | 2022-2025 | Opzelura |
| Ucb, INC. | $134.92 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $130.59 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $126.00 | 2019 | |
| Pfizer INC. | $112.15 | 2024-2025 | |
| Galderma Laboratories, L.P. | $101.96 | 2024-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $32.79 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $32.19 | 2025 | Dupixent |
| Almirall LLC | $22.82 | 2025 | Klisyri |
| Amgen INC. | $18.91 | 2025 | Otezla |
| Celgene Corporation | $17.25 | 2024 | Sotyktu |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $16.72 | 2023 | Vtama |
| Genzyme Corporation | $15.76 | 2022 | |
| Leo Pharma INC. | $14.49 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.